Business Wire

AlertEnterprise Looks to Transform Physical Security with Reveal of New Security AI Chatbot Powered by ChatGPT

Share

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today revealed the launch of its first-ever Guardian AI Chatbot powered by OpenAI ChatGPT. The company will debut the AI Chatbot globally end of March at the ASIS Europe and ISC West trade events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005630/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine. The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting. (Graphic: Business Wire)

The Guardian AI Chatbot is developed with the world-renowned GPT-3 platform created by OpenAI and is designed to instantly deliver security operators the physical access and security insights that matter most with quick questions and prompts.

“Physical security and access control systems have always contained a tremendous wealth of data but, until now, accessing it was a tedious and manual process,” said Yogesh Ailawadi, SVP Product and Solutions Engineering at AlertEnterprise. “Our Guardian AI Chatbot is poised to redefine the security operator’s experience, increasing their productivity by over 100 times with instant and actionable insights for not only risk mitigation but real business value.”

Mr. Ailawadi noted that the Guardian AI Chatbot is part of the launch of AlertEnterprise’s next-gen AI technology and is completely integrated throughout the Guardian platform.

Get powerful answers in an instant

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine.

The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting.

Some examples are:

  • “Guardian, how many people are on the Trading floor?”
  • “Guardian, how many employees and visitors are in the Data Center?”
  • “Guardian, how many new employee badges did we issue last month?”
  • “Guardian, show me upcoming employee training expirations for restricted area access.”

Drive costs down. Boost employee efficiency.

Using Guardian and its AI Chatbot, CSO and CISO’s can exponentially boost their team’s efficiency by automating tedious tasks and freeing up time to focus on more critical responsibilities. Guardian also leverages a company’s current security investments by connecting to most leading access control vendors and over 200 out-of-the-box connectors to HR, IT and OT systems. And if the organization has a complex mix of access control systems, Guardian connects to and consolidates them all under one platform.

AlertEnterprise founder and CEO Jasvir Gill says there’s no better time for CSO and CISO’s to invest in hyper-efficiency boosting AI platforms like Guardian. “Despite economic headwinds, the world’s most forward-looking CSO and CISO’s are accelerating security digital transformation. With Guardian’s deep forensics and AI data-driven insights, CSO and CISO’s can transform their access control from the stone age to the digital age—making every part of their SOC more automated, expeditious and cost effective, and ultimately the organization more secure. That’s why I view the AlertEnterprise Guardian platform as a deflationary fighting force for companies today.”

To see a live demonstration of the Guardian AI Chatbot, visit AlertEnterprise at Stand C5 at ASIS Europe in Rotterdam, NL, and Booth #13115 at ISC West in Las Vegas, USA.

AlertEnterprise

At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.

AlertEnterprise is committed to using AI in a responsible and ethical manner. We recognize the importance of protecting customer data and safeguarding against potential misuse of AI technology. As such, we have implemented strict policies and procedures to ensure the ethical use of AI and to protect the privacy and security of our customers' data. We believe that transparency and accountability are critical in this regard and remain dedicated to upholding these values throughout our development and operations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom